GET DAILY SIGNALSWhy Is Pro-Dex (PDEX) Stock Down -1.25% Today?
Key Takeaways
- PDEX shares traded down about 1.25% (roughly $0.88) on the day, easing to $69.42 from a prior-session close of $70.30.
- The pullback came without a single negative company headline, suggesting profit-taking and consolidation after a sharp multi-week rally that pushed the stock near its 52-week high.
- The stock had surged more than 11% in the prior session, leaving it technically extended and vulnerable to a modest retracement.
- Recent insider selling by executives and the company's high customer concentration remain overhangs cited by some traders.
- Broader small-cap and medical-device sentiment has been mixed, offering little external lift to offset the pause.
- Traders are watching whether the stock holds its 200-day moving average and whether volume confirms any further move.
- For deeper analysis, explore Price Targets, Earnings, and Forecast data on the dedicated pages.
- Discover actionable AI-driven trading ideas in the Trending AI Robots section.
Opening Summary
Pro-Dex, Inc. (PDEX), a small-cap medical-device manufacturer based in Irvine, California, designs and builds autoclavable, battery-powered and electric surgical drivers and shavers used primarily in orthopedic, thoracic, and craniomaxillofacial procedures. The company also produces rotary air motors for industrial and aerospace applications. In today's session, PDEX shares traded lower, slipping about 1.25% to $69.42, down roughly $0.88 from the prior close of $70.30. The decline reflected a natural pause after an unusually strong advance rather than any newly negative development, with markets attributing the move largely to profit-taking.
Profit-Taking After a Sharp Rally
The most direct driver of today's modest decline appears to be profit-taking following an outsized run. PDEX had surged more than 11% in the previous session and has more than tripled off its 52-week low, climbing into the low-$70s near its 52-week high of roughly $77. When a thinly traded micro-cap stock advances this quickly, short-term momentum traders and longer-term holders alike often lock in gains, producing a period of consolidation. Today's move, which trimmed only a small fraction of the recent rally, is consistent with that dynamic rather than a fundamental reversal.
Fundamental Strength Meets Concentration Risk
Beneath the price action, the company's fundamentals have improved. Its most recent quarterly report showed revenue growth of roughly 11% year over year and an earnings beat versus consensus, aided by strong demand for next-generation orthopedic instruments and a key customer contract extended through December 2028. Analyst coverage has also turned constructive, with a Buy rating and a recently raised price target. However, risks persist: a single customer is estimated to account for roughly three-quarters of sales, with the top three customers representing an even larger share, making results highly sensitive to any single relationship. Recent disclosed insider sales by the chief executive officer and chief financial officer have also drawn attention, even as they are relatively routine and small relative to their total holdings.
Market Context and Trading Activity
PDEX is a low-float micro-cap, so its daily trading volume tends to be modest and its price can move sharply on relatively little activity. The pullback today occurred without the stock breaking down through a major technical level, and it remains well above its 200-day moving average, a sign the broader uptrend is intact for now. The move also did not track a clear sector-wide decline, suggesting it was driven more by stock-specific positioning than by a broader medical-device or small-cap selloff. Given the prior session's double-digit gain, a modest giveback of this size is within normal volatility for a stock of this profile.
What Comes Next for PDEX
Looking ahead, investors will monitor whether PDEX can hold support near recent levels and whether the stock resumes its advance toward its 52-week high. Key considerations include the trajectory of orthopedic instrument demand, the stability of its concentrated customer base, and any further analyst or insider activity. Upcoming quarterly results will offer the next major fundamental checkpoint, while broader small-cap sentiment and healthcare-sector flows could influence near-term direction. As with any thinly traded stock, investors should weigh elevated volatility and concentration risk against the company's improving sales and earnings momentum.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that have demonstrated strong performance under current market conditions. Tickeron offers hundreds of automated bots covering thousands of tickers, with strategies, timeframes, performance metrics, and traded symbols varying widely. Only the strongest performers are featured in this section. Explore the Trending AI Robots page to see which automated strategies are currently standing out.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
PDEX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PDEX turned positive on November 04, 2026. Looking at past instances where PDEX's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PDEX's RSI Oscillator exited the oversold zone, 26 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 59 cases where PDEX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on PDEX as a result. In 86 of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
PDEX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +14.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where PDEX advanced for three days, in 242 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day moving average for PDEX crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDEX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
PDEX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PDEX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. PDEX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 44 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.247) is normal, around the industry mean (4.964). P/E Ratio (14.895) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.400) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.061) is also within normal values, averaging (56.876).
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of powered solutions
Industry PharmaceuticalsOther
Advertisement